Categories: News

NYSE Content Advisory: Pre-Market Update + ICE Data Shows October Home Prices Up 0.9%

NEW YORK, Nov. 10, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Kristen Scholer delivers the pre-market update on November 10th

- Advertisement -
  • Global equities are rallying Monday morning on hopes that the U.S government shutdown is nearing an end. On Sunday, the U.S. Senate advanced a bill that would reopen government after its longest shut down in history.
  • Intercontinental Exchange’s monthly mortgage monitor was released, showing home prices rose 0.9% annually in October, bucking nine straight months of contraction. Purchase demand held steady despite headwinds.
  • The 60th annual EEI Financial Conference kicked off in Florida yesterday, designed to connect leadership from investor-owned electric companies and the financial community.


Opening Bell


Eni (NYSE: E) celebrates 30th anniversary of listing

- Advertisement -


Closing Bell


Blackstone (NYSE: BX) celebrates its 40th anniversary of founding

- Advertisement -


Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2818565/NYSE_Market_Update_November_10.mp4 
Logo – https://mma.prnewswire.com/media/2581322/5612553/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update—ice-data-shows-october-home-prices-up-0-9-302610182.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

3 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

3 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

3 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

3 hours ago